REGN7508 + REGN9933 for Atrial Fibrillation

(ROXI-INCLINE Trial)

This trial tests two experimental drugs, REGN7508 and REGN9933, for individuals with atrial fibrillation, a condition where the heart beats irregularly and too fast, potentially causing blood clots. The primary goal is to determine if these drugs can safely prevent strokes or blood clots compared to a placebo, particularly for those who can't or choose not to take blood thinners. The trial will also assess any side effects and how the body responds to these drugs. Suitable candidates have atrial fibrillation and face a moderate to high risk of stroke but cannot take blood thinners due to bleeding risks. As a Phase 3 trial, this research represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. However, since the study is for people who cannot or choose not to take blood thinners, you might need to discuss your current medications with the study team.

A previous study found that REGN7508 caused blood clots in veins (VTE) in 7% of patients, while REGN9933 had a 17% rate of VTE. Both treatments met safety standards and did not cause major bleeding. Although some patients experienced blood clots, the treatments did not lead to serious bleeding issues. These rates suggest that both drugs are generally well-tolerated, with manageable side effects. This information may assist individuals considering participation in a clinical trial for these treatments.¹²³⁴⁵

Researchers are excited about REGN7508 and REGN9933 for atrial fibrillation because they promise unique approaches compared to standard treatments like beta-blockers, calcium channel blockers, and anticoagulants. REGN7508 and REGN9933 are designed to target specific pathways in heart rhythm regulation, offering the potential for more precise control of atrial fibrillation with possibly fewer side effects. Unlike conventional treatments that primarily focus on controlling heart rate and preventing clots, these investigational drugs may directly address the root causes of atrial fibrillation, potentially leading to more effective and targeted therapy.

This trial will evaluate the effectiveness of REGN7508 and REGN9933 for atrial fibrillation. Studies have shown that REGN7508 may help prevent blood clots, which can cause strokes, in people with atrial fibrillation. REGN7508 has effectively stopped clots while reducing the risk of bleeding, a common issue with traditional blood thinners. Early results suggest it might even outperform some current treatments. REGN9933, another treatment option in this trial, has also reduced clots without causing significant bleeding. Both drugs target Factor XI, a protein involved in clot formation, to prevent clots from forming. Overall, both treatments have shown promise for improving heart health in patients with atrial fibrillation.¹²³⁶⁷